Sprycel

(Dasatinib)

ApprovedProtein / enzyme

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Dasatinib is used to treat certain types of blood cancers, particularly chronic myeloid leukemia and acute lymphoblastic leukemia, by stopping cancer cells from growing and multiplying.[2] Sprycel is currently approved and in use across 36 indications[4].[1]

Sprycel is one of 676 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Approved.

Indications

322

Total Trials

Active Trials

675

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Acute Myeloid LeukemiaRecruiting

Liver DiseaseActive, not recruiting

Chronic Myelogenous LeukemiaRecruiting

Bladder Transitional Cell CarcinomaActive, not recruiting

Breast CancerCompleted

Transitional Cell CarcinomaActive, not recruiting

Advanced LymphomaActive, not recruiting

Mild Cognitive ImpairmentActive, not recruiting

Chronic Myeloid Leukemia, BCR-ABL1 PositiveActive, not recruiting

HIV InfectionsRecruiting

Acute Myeloid LeukemiaPhase 2

Recruiting

Liver DiseasePreclinical

Active, not recruiting

Chronic Myelogenous LeukemiaApproved

Recruiting

Bladder Transitional Cell CarcinomaPreclinical

Active, not recruiting

Breast CancerPhase 2

Completed

Transitional Cell CarcinomaPreclinical

Active, not recruiting

Advanced LymphomaPhase 2

Active, not recruiting

Mild Cognitive ImpairmentPreclinical

Active, not recruiting

Chronic Myeloid Leukemia, BCR-ABL1 PositivePhase 2

Active, not recruiting

HIV InfectionsPhase 1

Recruiting

Showing 10 of 36 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

14 2

Zolymbus

AbbVie

Preclinical

1 3

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 4

Duragesic

CCephalon

Preclinical

1 5

Acupan

YYonsei University

Preclinical

1 6

Nubain

AAultman Health Foundation

Preclinical

1 7

Vfend

PPrism Pharmaceuticals

Rilvegostomig

1 9

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

1 10

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Prostate Cancer

NCT01990196

Q4 2026

Phase 1Recruiting

Acute Lymphoblastic Leukemia

NCT04872790

Post-ApprovalRecruiting

Children

NCT03844360

Q1 2027

Phase 2Recruiting

Acute Lymphoblastic Leukemia

NCT04747912

Phase 1Active, not recruiting

Advanced Hematologic Malignancies

NCT06645886

Q2 2027

Phase 1Active, not recruiting

Acute Lymphoblastic Leukemia

NCT05993949

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia26 trials

Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT00345826·19 enrolled

Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)

Completed·GGoethe University·Phase 2·NCT01724879·19 enrolled

BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00103701

Show 23 more trials

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

Recruiting·UUniversity of Chicago·Phase 2·NCT04747912·25 enrolled

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00036738·28 enrolled

Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic Leukemia

Completed·VVersailles Hospital·Phase 2·NCT02888990·71 enrolled

Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00940524·7 enrolled

Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Unknown status·GGruppo Italiano Malattie EMatologiche dell'Adulto··NCT03318770·60 enrolled

Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients

Unknown status·TTongji Hospital·Phase 4·NCT02690922·40 enrolled

Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

Active, not recruiting·SStanford University·Phase 1·NCT05993949·8 enrolled

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2/3·NCT03117751·790 enrolled

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Completed·OOHSU Knight Cancer Institute·Phase 1·NCT02779283·7 enrolled

Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia

Completed·GGrupo Espanol de trasplantes hematopoyeticos y terapia celular·Phase 2·NCT01310010·30 enrolled

Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01460160·106 enrolled

D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia

Unknown status·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT02744768·60 enrolled

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Recruiting·OOHSU Knight Cancer Institute·Phase 1·NCT04872790·20 enrolled

Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04329325·17 enrolled

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2/3·NCT00720109·63 enrolled

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02420717·11 enrolled

Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT02523976·30 enrolled

Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00982488·238 enrolled

Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Terminated·NNorthwestern University·Phase 1·NCT02819804·1 enrolled

Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00101595·96 enrolled

Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

Completed·—·Phase 1·NCT00816283·5 enrolled

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01256398·66 enrolled

Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00316953·48 enrolled

Myeloid Leukemia18 trials

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Active, not recruiting·SSWOG Cancer Research Network·Phase 2·NCT03654768·81 enrolled

Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia

Completed·NNorwegian University of Science and Technology·Phase 2·NCT01725204·40 enrolled

Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00324077

Show 15 more trials

Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00101660·387 enrolled

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01751425·8 enrolled

KRT-232 and TKI Study in Chronic Myeloid Leukemia

Recruiting·KKartos Therapeutics, Inc.·Phase 1/2·NCT04835584·109 enrolled

Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02389972·128 enrolled

Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00103844·150 enrolled

Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

Unknown status·PPETHEMA Foundation·Phase 2·NCT01802450·18 enrolled

Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment

Unknown status·AAmsterdam UMC, location VUmc·Phase 2·NCT03573596·134 enrolled

A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib

Completed·KKanto CML Study Group·Phase 2·NCT01342679·21 enrolled

Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01850004·84 enrolled

Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT01660906·39 enrolled

Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

Unknown status·SShimousa Hematology Study Group·Phase 2·NCT01627132·50 enrolled

A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00481247·547 enrolled

A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00482703·23 enrolled

Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase

Completed·PPoitiers University Hospital·Phase 2·NCT01872442

Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00101816·124 enrolled

Breast Cancer14 trials

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00371345·92 enrolled

S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone

Completed·SSWOG Cancer Research Network·Phase 2·NCT00410813·85 enrolled

A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00371254·55 enrolled

Show 11 more trials

Phase II Dasatinib Study in Advanced Breast Cancer

Completed·—·Phase 2·NCT00546104·31 enrolled

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT00903006·11 enrolled

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00696072·120 enrolled

Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00452673·52 enrolled

Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01471106·26 enrolled

Personalized Treatment Selection for Metastatic Breast Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00780676·97 enrolled

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Recruiting·FFudan University·Phase 2·NCT06355037·10 enrolled

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00754325·100 enrolled

Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR

Terminated·UUniversity of Wisconsin, Madison·Phase 2·NCT02720185·5 enrolled

Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT05198843·1 enrolled

Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer

Completed·AAccelerated Community Oncology Research Network·Phase 1/2·NCT00924352·56 enrolled

Chronic Myelogenous Leukemia10 trials

Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00123474·724 enrolled

BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT00064233·42 enrolled

Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01426334·4 enrolled

Show 7 more trials

Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia

Unknown status·HHospital Universitario Dr. Jose E. Gonzalez·Phase 2·NCT05638763·15 enrolled

A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00298987·400 enrolled

BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

Unknown status·JJonsson Comprehensive Cancer Center·Phase 2·NCT00112775

Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00254423·150 enrolled

Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00123487·638 enrolled

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT01498445·32 enrolled

Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00978731·46 enrolled

Prostate Cancer7 trials

Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

Completed·UUniversity of California, Irvine·Phase 2·NCT00570700·38 enrolled

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

Terminated·—·Phase 2·NCT00918385·57 enrolled

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT01990196·45 enrolled

Show 4 more trials

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00439270·49 enrolled

Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00744497·1,930 enrolled

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00385580·94 enrolled

Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Unknown status·UUniversity of Southern California·Phase 2·NCT01685125·96 enrolled

89 more indications

Chronic Lymphocytic Leukemia7 trials

A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia

Withdrawn·SScripps Health·Phase 1/2·NCT00829647

A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia

Terminated·UUniversity of California, San Diego·Phase 1/2·NCT00949988·3 enrolled

Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease

Unknown status·—·Phase 2·NCT01051115·35 enrolled

Show 4 more trials

Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00563290·7 enrolled

Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00364286·17 enrolled

Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00872976

Dasatinib in Relapsed Chronic Lymphocytic Leukemia

Completed·MMassachusetts General Hospital·Phase 2·NCT00438854·15 enrolled

Treatment6 trials

Treatment of Adult Ph+ LAL With BMS-354825

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT00391989·53 enrolled

Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02297139·17 enrolled

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT04439305

Show 3 more trials

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01260688·22 enrolled

Treatment-free Remission Accomplished With Dasatinib in Patients With CML

Unknown status·UUniversity Health Network, Toronto·Phase 2·NCT02268370·131 enrolled

De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia

Completed·UUniversity of Liverpool·Phase 2·NCT01804985·174 enrolled

Non-Small Cell Lung Cancer6 trials

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT01999985·25 enrolled

Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer

Terminated·—·Phase 2·NCT00564876·2 enrolled

Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00858403·7 enrolled

Show 3 more trials

Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00459342·35 enrolled

Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Terminated·CChul Kim·Phase 1/2·NCT02954523·10 enrolled

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00826449·53 enrolled

Acute Myeloid Leukemia5 trials

Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE

Recruiting·IInstitut Paoli-Calmettes·Phase 2·NCT06055621·35 enrolled

The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Unknown status·IInstitute of Hematology & Blood Diseases Hospital, China·N/A·NCT03173612·132 enrolled

Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia

Terminated·—·Phase 1/2·NCT01876953·20 enrolled

Show 2 more trials

Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Completed·UUniversity of Ulm·Phase 1/2·NCT00850382·89 enrolled

Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation

Withdrawn·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT03560908

Multiple Myeloma3 trials

Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients

Terminated·FFondazione EMN Italy Onlus·Phase 2·NCT01116128·8 enrolled

A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma

Completed·WWashington University School of Medicine·Phase 2·NCT00429949·21 enrolled

Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00560352·16 enrolled

Alzheimer's Disease3 trials

Senolytic Therapy to Modulate Progression of Alzheimer's Disease

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1/2·NCT04063124·5 enrolled

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT04685590·48 enrolled

Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease

Completed·LLewis Lipsitz·Phase 1/2·NCT05422885·15 enrolled

Gastrointestinal Stromal Tumor2 trials

Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01643278·29 enrolled

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

Completed·SSwiss Cancer Institute·Phase 2·NCT00568750·47 enrolled

Trial2 trials

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial

Unknown status·KKanto CML Study Group·Phase 2·NCT01887561·100 enrolled

Tics2 trials

The Effect of Omeprazole on the Pharmacokinetics of Dasatinib in Healthy Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00655746·14 enrolled

Senolytics for Secondary Progressive MS

Not yet recruiting·OOhio State University·Phase 1·NCT07270120·30 enrolled

Chemotherapy2 trials

A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·N/A·NCT05026229·60 enrolled

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)

Completed·UUniversity of Ulm·Phase 3·NCT02013648·204 enrolled

ART2 trials

Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01392703·141 enrolled

KISS Study: Kinase Inhibition With Sprycel Start up

Unknown status·UUniversity of Auckland, New Zealand·Phase 2·NCT03193281·91 enrolled

Patients With Advanced Solid Tumors2 trials

Study of Dasatinib in Patients With Advanced Solid Tumors

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00162214·60 enrolled

Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

Completed·MMayo Clinic·Phase 1·NCT00662636·27 enrolled

Endometrial Cancer2 trials

Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01440998·18 enrolled

Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer

Completed·UUniversity of Virginia·Phase 1·NCT01482728·12 enrolled

CML2 trials

Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00337454·48 enrolled

Rollover Study of BMS-354825 in Patients With CML and Ph+ALL

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT01030718·54 enrolled

Glioblastoma2 trials

Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00948389·28 enrolled

Pilot Trial for Treatment of Recurrent Glioblastoma

Recruiting·AAHS Cancer Control Alberta·Phase 1·NCT05432518·10 enrolled

Leukemia2 trials

Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00306202·63 enrolled

Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia

Completed·UUniversity Hospital, Angers·Phase 2·NCT02113319·27 enrolled

Advanced Sarcoma1 trial

Trial of Dasatinib in Advanced Sarcomas

Completed·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT00464620·366 enrolled

Advanced NSCLC1 trial

Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC

Terminated·—·Phase 2·NCT00787267·37 enrolled

Primary Peritoneal Carcinoma1 trial

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Completed·GGynecologic Oncology Group·Phase 2·NCT00671788·35 enrolled

Children1 trial

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Recruiting·WWei Zhao·Phase 4·NCT03844360·1,500 enrolled

Advanced Cancers1 trial

Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01514864·19 enrolled

Stem Cell Transplant1 trial

Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML

Not yet recruiting·TThe University of Hong Kong·Phase 2·NCT07493408·45 enrolled

Glioblastoma Multiforme1 trial

Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00423735·64 enrolled

Hematologic Malignancies1 trial

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Terminated·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT01643603·5 enrolled

Pediatric Patients1 trial

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

Unknown status·SSeattle Children's Hospital·N/A·NCT02015728·20 enrolled

Molecular Targeted Therapy1 trial

Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma

Completed·UUniversity of Regensburg·Phase 2·NCT02596828·4 enrolled

COVID-191 trial

Dasatinib for the Treatment of Moderate and Severe COVID-19

Withdrawn·UUniversity of Southern California·Phase 2·NCT04830735

Fasting Conditions1 trial

Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

Completed·XXspray Pharma AB·Phase 1·NCT05433896·17 enrolled

Breast Carcinoma1 trial

Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00820170·55 enrolled

Randomized1 trial

The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder

Available·PPusan National University Hospital··NCT00854841

Dexamethasone1 trial

Dasatinib in Combination With Revlimid (and Dexamethasone)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00560391·35 enrolled

Childhood Cancer1 trial

An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT04733534·110 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease

Completed·—·Phase 1/2·NCT05506488·30 enrolled

Idiopathic Pulmonary Fibrosis1 trial

Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial

Completed·WWake Forest University Health Sciences·Phase 1·NCT02874989·26 enrolled

Aging1 trial

Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging

Unknown status·TTruDiagnostic·Phase 2·NCT04946383·25 enrolled

Carboplatin1 trial

PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer

Completed·AAA Secord·Phase 1·NCT00672295·11 enrolled

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT02059265·35 enrolled

HER2 Positive1 trial

Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients

Completed·SSpanish Breast Cancer Research Group·Phase 1/2·NCT01306942·37 enrolled

PTCL1 trial

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Unknown status·RRuijin Hospital·Phase 1/2·NCT05559008·116 enrolled

Glioma1 trial

Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT03352427·3 enrolled

Mastocytosis1 trial

Evaluation of Response of Dasatinib to Treat Mastocytosis

Unknown status·FFederico II University·Phase 2·NCT00979160·30 enrolled

Advanced Cancer1 trial

Dasatinib and Crizotinib in Advanced Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01744652·62 enrolled

Mucosal Melanoma1 trial

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00700882·81 enrolled

Philadelphia Chromosome Positive1 trial

Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2/3·NCT00349518

Tyrosine Kinase Inhibitors1 trial

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

Completed·UUNC Lineberger Comprehensive Cancer Center··NCT03885830·45 enrolled

Liver Cancer1 trial

Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00459108·25 enrolled

Ablation1 trial

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01254864·190 enrolled

Leukaemia1 trial

Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia

Completed·NNewcastle University·Phase 3·NCT01460693·814 enrolled

Diffuse Intrinsic Pontine Glioma1 trial

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT02233049·250 enrolled

Lymphoma1 trial

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00608361·80 enrolled

Tyrosine Kinase Inhibitor1 trial

Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02733445·2,650 enrolled

Squamous Cell Carcinoma1 trial

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

Terminated·—·Phase 2·NCT01488318·21 enrolled

Triple-Negative Breast Cancer1 trial

Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients

Terminated·BBaylor Breast Care Center·Phase 2·NCT00817531·22 enrolled

Metastatic Melanoma1 trial

Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma

Completed·—·Phase 2·NCT01876212·15 enrolled

Rhabdomyosarcoma1 trial

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT03041701·14 enrolled

Pediatric1 trial

Newly-diagnosed Pediatric T-cell ALL Protocol

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2/3·NCT06855810·610 enrolled

Advanced1 trial

Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00529763·121 enrolled

Relapsed or Refractory1 trial

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Unknown status·SSamsung Medical Center·Phase 2·NCT02638428·90 enrolled

Intestinal Cancer1 trial

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Completed·AAnne Noonan·Phase 1·NCT04164069·9 enrolled

Colorectal Cancer1 trial

Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00835679·9 enrolled

Advanced Solid Malignancies1 trial

Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.

Completed·AAmsterdam UMC, location VUmc·N/A·NCT01636908·43 enrolled

Recurrent or Metastatic1 trial

Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00859937·55 enrolled

Transitional Cell Carcinoma1 trial

Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder

Completed·HHoosier Cancer Research Network·N/A·NCT00706641·25 enrolled

Malignancies1 trial

Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

Withdrawn·EEDDC (Experimental Drug Development Centre), A*STAR Research Entities·Phase 1·NCT03414450

Polycythemia Vera1 trial

Dasatinib in Polycythemia Vera

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT00538980·10 enrolled

Melanoma1 trial

Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00436605·39 enrolled

Macroglobulinemia1 trial

Dasatinib In Waldenström Macroglobulinemia

Terminated·—·Phase 1·NCT04115059·3 enrolled

Metastatic Colorectal Cancer1 trial

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Recruiting·OOslo University Hospital·Phase 2·NCT05725200·40 enrolled

Advanced Solid Tumors1 trial

Gemcitabine and Dasatinib in Advanced Solid Tumors

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00429234·54 enrolled

Androgen Deprivation Therapy1 trial

Study of Dasatinib, Androgen Deprivation Therapy and Radiation

Withdrawn·—·Phase 1·NCT01826838

Ph+ ALL1 trial

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Completed· Novartis logo

Novartis·Phase 1·NCT02081378·326 enrolled

Quality of Life1 trial

Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

Completed·AAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia·Phase 3·NCT02326311·229 enrolled

Efficacy and Safety1 trial

The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients

Unknown status·SShenzhen Second People's Hospital·Phase 4·NCT04933526·118 enrolled

Advanced Hematologic Malignancies1 trial

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

Active, not recruiting·KKumquat Biosciences Inc.·Phase 1·NCT06645886·13 enrolled

Liver1 trial

A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT00382668·40 enrolled

Phase 21 trial

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01357655·70 enrolled

Intrahepatic Cholangiocarcinoma1 trial

Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma

Completed·MMassachusetts General Hospital·Phase 2·NCT02428855·8 enrolled

Blinatumomab1 trial

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Recruiting·MMarlise Luskin, MD·Phase 1·NCT03595917·40 enrolled

Pancreatic Cancer1 trial

Dasatinib in Treating Patients With Stage IV Pancreatic Cancer

Terminated·—·Phase 2·NCT00544908·7 enrolled

Hematological Malignancies1 trial

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Recruiting·PPrincess Maxima Center for Pediatric Oncology·Phase 1/2·NCT05751044·26 enrolled

Humans1 trial

Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

Completed·—·Phase 2·NCT04313634·74 enrolled

Myelodysplastic Syndrome1 trial

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

Completed·HH. Lee Moffitt Cancer Center and Research Institute·N/A·NCT00624585·18 enrolled

Gastric1 trial

Effects of Gastric pH on the Pharmacokinetics of Dasatinib

Completed·UUniversity of California, San Francisco·Phase 1·NCT01398046·10 enrolled

Refractory1 trial

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

Terminated·MMassachusetts General Hospital·Phase 2·NCT01173679·10 enrolled

Solid Tumors1 trial

Solid Tumors Using Ixabepilone and Dasatinib

Completed·MMedstar Health Research Institute·Phase 1·NCT00717704·19 enrolled

Diffuse Large B-Cell Lymphoma1 trial

A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT00918463·2 enrolled

Unspecified3 trials

Study of Erlotinib in Combination With Dasatinib

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00895128·65 enrolled

A Phase I/Expansion Study of Dasatinib

Terminated·—·Phase 1·NCT00598091·30 enrolled

Explore the Synergy of Combination TKI Therapy

Withdrawn·UUniversity of Florida·Phase 1·NCT02129166

Regulatory

FDA Approval Timeline[5]

Jun 28, 2006

SPRYCEL

NDA NDA021986

Nov 8, 2007

SPRYCEL

NDA NDA021986

Nov 8, 2007

SPRYCEL

NDA NDA021986

May 30, 2008

SPRYCEL

NDA NDA021986

May 21, 2009

SPRYCEL

NDA NDA021986

Jul 28, 2010

SPRYCEL

NDA NDA021986

Oct 28, 2010

SPRYCEL

NDA NDA021986

Oct 28, 2010

SPRYCEL

NDA NDA021986

Oct 7, 2011

SPRYCEL

NDA NDA021986

Oct 7, 2011

SPRYCEL

NDA NDA021986

Jun 17, 2013

SPRYCEL

NDA NDA021986

Apr 10, 2014

SPRYCEL

NDA NDA021986

Jan 26, 2015

SPRYCEL

NDA NDA021986

Aug 12, 2015

SPRYCEL

NDA NDA021986

Aug 12, 2015

SPRYCEL

NDA NDA021986

Sep 27, 2016

SPRYCEL

NDA NDA021986

Aug 10, 2017

SPRYCEL

NDA NDA021986

Nov 9, 2017

SPRYCEL

NDA NDA021986

Nov 15, 2018

SPRYCEL

NDA NDA021986

Dec 21, 2018

SPRYCEL

NDA NDA021986

Jun 29, 2021

SPRYCEL

NDA NDA021986

Feb 8, 2023

SPRYCEL

NDA NDA021986

Dec 5, 2023

PHYRAGO

NDA NDA216099

Jul 31, 2024

SPRYCEL

NDA NDA021986

Sources

References

[1]
ClinicalTrials.gov — 322 trial records for Dasatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Sprycel drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Dasatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Dasatinib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021986). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Sprycel. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Karuna Therapeutics, Inc., a Bristol Myers Squibb company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Bcr/abl Fusion Protein Inhibitor[3]
Modality: Protein / enzyme[3]
Highest Phase: Approved[1]
Company: KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Patent Landscape[6]

Patent Cliff

Sep 28, 2026

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7491725Mar 28, 2026

7491725*PEDSep 28, 2026

11202778Jan 22, 2041

12433891Jan 22, 2041

12544376Jan 22, 2041

3 more patents

11298356Jan 22, 2041

12465606Jan 22, 2041

11324745Jan 22, 2041

Sprycel

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Acute Lymphoblastic Leukemia26 trials

Myeloid Leukemia18 trials

Breast Cancer14 trials

Chronic Myelogenous Leukemia10 trials

Prostate Cancer7 trials

Chronic Lymphocytic Leukemia7 trials

Treatment6 trials

Non-Small Cell Lung Cancer6 trials

Acute Myeloid Leukemia5 trials

Multiple Myeloma3 trials

Alzheimer's Disease3 trials

Gastrointestinal Stromal Tumor2 trials

Trial2 trials

Tics2 trials

Chemotherapy2 trials

ART2 trials

Patients With Advanced Solid Tumors2 trials

Endometrial Cancer2 trials

CML2 trials

Glioblastoma2 trials

Leukemia2 trials

Advanced Sarcoma1 trial

Advanced NSCLC1 trial

Primary Peritoneal Carcinoma1 trial

Children1 trial

Advanced Cancers1 trial

Stem Cell Transplant1 trial

Glioblastoma Multiforme1 trial

Hematologic Malignancies1 trial

Pediatric Patients1 trial

Molecular Targeted Therapy1 trial

COVID-191 trial

Fasting Conditions1 trial

Breast Carcinoma1 trial

Randomized1 trial

Dexamethasone1 trial

Childhood Cancer1 trial

Non-Alcoholic Fatty Liver Disease1 trial

Idiopathic Pulmonary Fibrosis1 trial

Aging1 trial

Carboplatin1 trial

Dacarbazine1 trial

CAR T Cell Therapy1 trial

Peritoneal Cancer1 trial

HER2 Positive1 trial

PTCL1 trial

Glioma1 trial

Mastocytosis1 trial

Advanced Cancer1 trial

Mucosal Melanoma1 trial

Philadelphia Chromosome Positive1 trial

Tyrosine Kinase Inhibitors1 trial

Liver Cancer1 trial

Ablation1 trial

Leukaemia1 trial

Diffuse Intrinsic Pontine Glioma1 trial

Lymphoma1 trial

Tyrosine Kinase Inhibitor1 trial

Squamous Cell Carcinoma1 trial

Triple-Negative Breast Cancer1 trial

Metastatic Melanoma1 trial

Rhabdomyosarcoma1 trial

Pediatric1 trial

Advanced1 trial

Relapsed or Refractory1 trial

Intestinal Cancer1 trial

Colorectal Cancer1 trial

Advanced Solid Malignancies1 trial

Recurrent or Metastatic1 trial

Transitional Cell Carcinoma1 trial

Malignancies1 trial